Home
July 2008 August 2008 September 2008
Su Mo Tu We Th Fr Sa
Week 31 1 2
Week 32 3 4 5 6 7 8 9
Week 33 10 11 12 13 14 15 16
Week 34 17 18 19 20 21 22 23
Week 35 24 25 26 27 28 29 30
Week 36 31

A Simple Validated Scale to Measure Urgency - Abstract Show Comments PDF Print E-mail
  
Monday, 18 February 2008

Department of Medicine, Archway Campus, Whittington Hospital, University College London and Department of Urology, Whittington Hospital, London, United Kingdom.

We validated a simple scale to measure urinary urgency.

The new 10-item scale was validated using data from experiments using a single group repeated measure design. A total of 475 patients, including 411 females and 64 males, with a mean age of 57.3 years who had been diagnosed with overactive bladder were treated with a bladder retraining regimen and antimuscarinic agent (10 mg oxybutynin controlled release per night or 4 mg tolterodine slow release per night). At each visit patient urge symptoms were recorded by the scale. Reported average daily frequency and incontinence episodes were also recorded. Of patients who were not satisfied with the symptoms 130 had 25 mg imipramine per night added to their prescription and in 130 treatment was changed to 10 mg solifenacin per night.

Construct validity was tested by comparing the urgency scale to frequency and to incontinence (Spearman's rank correlation coefficient r = 0.38, p < 0.001 and r = 0.15, p < 0.001, respectively). Internal consistency showed Cronbach's alpha = 0.83. Test-retest reliability was determined in 30 patients and interobserver reliability was determined in 58 (Pearson's r = 0.99, p < 0.001 and r = 0.99, p < 0.001, respectively). Internal responsiveness in the imipramine add-on study in 130 patients showed a standardized response mean of 0.6 (p < 0.001) and in the solifenacin swap study in 130 it showed a standardized response mean of 0.69, while external responsiveness showed a standardized response mean of 0.69 (each p < 0.001).

This scale succeeded in all validation studies. This new scale may prove useful for measuring between-drug differences in efficacy and for monitoring treatment responses in patients with overactive bladder. It now must be tested in a proper double-blind, randomized, controlled trial.

Written by
Al-Buheissi S, Khasriya R, Maraj BH, Malone-Lee J

Reference
J Urol. 2008 Jan 17. Epub ahead of print.
doi:10.1016/j.juro.2007.10.075

PubMed Abstract
PMID:18206957

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 2
PoorBest


 
Visitor Ratings:
Healthcare Professionals:
4 (2 votes)